Lesson plan

Fluvoxamine

{{Infobox drug | Verifiedfields = changed | Watchedfields = changed | verifiedrevid = 443824781 | image = Fluvoxamine.svg | image_class = skin-invert-image | width = | alt = | caption = | image2 = Fluvoxamine 3D 4ENH.png | image_class2 = bg-transparent | width2 = | alt2 = | pronounce = UK: US: | tradename = Luvox, others | Drugs.com = | MedlinePlus = a695004 | DailyMedID = Fluvoxamine | pregnancy_AU = C | pregnancy_AU_comment = | pregnancy_category = | routes_of_administration = By mouth | class = Selective serotonin reuptake inhibitor (SSRI) | ATC_prefix = N06 | ATC_suffix = AB08 | ATC_supplemental = | legal_AU = S4 | legal_AU_comment = | legal_BR = C1 | legal_BR_comment = | legal_CA = Rx-only | legal_CA_comment = | legal_DE = | legal_DE_comment = | legal_NZ = | legal_NZ_comment = | legal_UK = POM | legal_UK_comment = | legal_US = Rx-only | legal_US_comment = | legal_UN = | legal_UN_comment = | legal_status = | bioavailability = 53% (90% confidence interval: 44–62%) | protein_bound = 77–80% | metabolism = Liver (primarily O-demethylation) Major: CYP2D6 or CYP1A2 Minor: CYP3A4, CYP2C19, and/or CYP1A2 | metabolites = | onset = | elimination_half-life = 12–13 hours (single dose), 22 hours (repeated dosing) | duration_of_action = | excretion = Kidney (98%; 94% as metabolites, 4% as unchanged drug) | CAS_number_Ref = | CAS_number = 54739-18-3 | CAS_supplemental = | PubChem = 532434…

Back to article

Article summary

{{Infobox drug | Verifiedfields = changed | Watchedfields = changed | verifiedrevid = 443824781 | image = Fluvoxamine.svg | image_class = skin-invert-image | width = | alt = | caption = | image2 = Fluvoxamine 3D 4ENH.png | image_class2 = bg-transparent | width2 = | alt2 = | pronounce = UK: US: | tradename = Luvox, others | Drugs.com = | MedlinePlus = a695004 | DailyMedID = Fluvoxamine | pregnancy_AU = C | pregnancy_AU_comment = | pregnancy_category = | routes_of_administration = By mouth | class = Selective serotonin reuptake inhibitor (SSRI) | ATC_prefix = N06 | ATC_suffix = AB08 | ATC_supplemental = | legal_AU = S4 | legal_AU_comment = | legal_BR = C1 | legal_BR_comment = | legal_CA = Rx-only | legal_CA_comment = | legal_DE = | legal_DE_comment = | legal_NZ = | legal_NZ_comment = | legal_UK = POM | legal_UK_comment = | legal_US = Rx-only | legal_US_comment = | legal_UN = | legal_UN_comment = | legal_status = | bioavailability = 53% (90% confidence interval: 44–62%) | protein_bound = 77–80% | metabolism = Liver (primarily O-demethylation) Major: CYP2D6 or CYP1A2 Minor: CYP3A4, CYP2C19, and/or CYP1A2 | metabolites = | onset = | elimination_half-life = 12–13 hours (single dose), 22 hours (repeated dosing) | duration_of_action = | excretion = Kidney (98%; 94% as metabolites, 4% as unchanged drug) | CAS_number_Ref = | CAS_number = 54739-18-3 | CAS_supplemental = | PubChem = 532434…

Key claims

No claims recorded.

Discussion questions

  1. Summarise the article in your own words. Which single claim would you verify first, and why?
  2. Which claim in this article is most likely to be revised as the sources update? How would you check its current status?
  3. If two sources disagreed about one of these facts, what would you need in order to trust one over the other?

Bibliography

No sources recorded.

Key claims and bibliography are generated from the same tracked claims and sources as the article page.